Search Results: PARP inhibitor

New drug trial to target hereditary cancers

Cancer Research UK scientists at Newcastle University are starting the first UK trial of a new drug which targets the 'Achilles' heel' in hereditary forms of both breast and ovarian cancer. Cancer Research UK scientists at Newcastle University are starting the first UK trial of a new drug which targets the 'Achilles' heel' in hereditary forms of both breast and ovarian cancer.

27 February 2008

Newcastle scientists host top conference in Gateshead

Newcastle scientists will play host to an international audience of researchers and doctors at a major conference in Gateshead from 5-7 October 2005. Newcastle scientists will play host to an international audience of researchers and doctors at a major conference in Gateshead from 5-7 October 2005.

4 October 2005

• Health & Medicine

New drug could help target cancer cells with deadly accuracy

A new drug that could revolutionise the impact of radiotherapy on cancer and make treatment much more effective, has been developed by Cancer Research UK scientists - it is announced today. A new drug that could revolutionise the impact of radiotherapy on cancer and make treatment much more effective, has been developed by Cancer Research UK scientists - it is announced today.

28 October 2002

• Policy & Insight

Opinion: 'Let’s not be short-sighted – the UK’s medical research charities need urgent support'

Today’s new figures, from the UK’s National Cancer Research Institute, project a devastating 24% drop in the UK’s overall cancer research spending this year, driven by a 46% fall in charity sector funding. Today’s new figures, from the UK’s National Cancer Research Institute, project a devastating 24% drop in the UK’s overall cancer research spending this year, driven by a 46% fall in charity sector funding.

24 September 2020

• Science & Technology

ASCO 2019 news: targeted treatment takeover, drugging the ‘undruggable’, obesity and blood tests

The 2019 ASCO conference news highlights: a year of progress with targeted drugs trialled in prostate, pancreatic, breast and lung cancers. The 2019 ASCO conference news highlights: a year of progress with targeted drugs trialled in prostate, pancreatic, breast and lung cancers.

31 May 2019

• Health & Medicine
• Science & Technology

News digest - drug approval, flexible pressure sensor, pen-sized microscope, engineered molecules and… olive oil?

Cancer drugs approved, a tiny microscope for spotting cancer cells, engineering molecules so cells can ‘sense’ and why some £5 olive oil isn’t worth it. Cancer drugs approved, a tiny microscope for spotting cancer cells, engineering molecules so cells can ‘sense’ and why some £5 olive oil isn’t worth it.

30 January 2016

• Science & Technology
• Health & Medicine

Recently funded research – understanding what makes cancer tick

Here are a few highlights from the research projects our Science Committee funded in April. Here are a few highlights from the research projects our Science Committee funded in April.

2 October 2015

• Health & Medicine

A disappointing decision over olaparib for ovarian cancer

In light of a preliminary 'no' from NICE over olaparib for ovarian cancer, we hear from one of our experts whose work led to the drug's development In light of a preliminary 'no' from NICE over olaparib for ovarian cancer, we hear from one of our experts whose work led to the drug's development

1 June 2015

• Science & Technology
• Health & Medicine

News digest - new immunotherapy results, ‘personalised vaccines’, an ‘injectable lab’ and more

New immunotherapy results from a big US conference, another first step towards ‘personalised cancer vaccines’, plus what’s an ‘injectable lab’? New immunotherapy results from a big US conference, another first step towards ‘personalised cancer vaccines’, plus what’s an ‘injectable lab’?

25 April 2015

Cancer Research UK announces winners of 2013 research prizes

Cancer Research UK presented its prestigious Lifetime Achievement Award to the internationally acclaimed scientist Professor Sir Bruce Ponder. Cancer Research UK presented its prestigious Lifetime Achievement Award to the internationally acclaimed scientist Professor Sir Bruce Ponder.

5 November 2013

• Science & Technology

Researchers exploit cancer’s faulty defence mechanism

Researchers in Germany have found a new way to exploit the differences between cancer cells and normal cells that could lead to new treatments. Researchers in Germany have found a new way to exploit the differences between cancer cells and normal cells that could lead to new treatments.

12 June 2013